Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | DRD4 | P21917 | 3/20 | 0.59 |
| ▸ | DRD3 | P35462 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13280911 | 0.87 | HPGD (0.60) | ALDH1A1KDM4ESMN1; SMN2CD274HPGD | |
| Hydrochloric Acid SCHEMBL16654226 | 0.86 | HPGD (0.58) | ALDH1A1KDM4ESMN1; SMN2CD274HPGD | |
| SCHEMBL2774517 | 0.85 | DRD4 (0.64) | ALDH1A1SMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL13492542 | 0.84 | KMT2A (0.71) | ALDH1A1SMN1; SMN2CD274DRD2DRD4 | |
| SCHEMBL14864329 | 0.84 | ALDH1A1 (0.74) | ALDH1A1SMN1; SMN2CD274DRD2DRD4 | |
| SCHEMBL487964 | 0.84 | CD274 (0.84) | ALDH1A1KDM4ESMN1; SMN2CD274HPGD | |
| SCHEMBL3174309 | 0.83 | DRD4 (0.62) | ALDH1A1DRD2DRD4DRD3KMT2A | |
| SCHEMBL2772319 | 0.83 | SMN1; SMN2 (0.72) | ALDH1A1SMN1; SMN2HPGDDRD3KMT2A | |
| SCHEMBL1382764 | 0.82 | SMN1; SMN2 (0.95) | ALDH1A1KDM4ESMN1; SMN2CD274HPGD | |
| SCHEMBL12090046 | 0.81 | LMNA (0.58) | ALDH1A1CD274HPGDKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| EP-4526291-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | The Board of Regents of the University of Texas System (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240383884-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. | 2024-11-21 | — | — | US | disclosed |
| WO-2023225327-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | disclosed |
| US-10752640-B2 | Compounds active towards bromodomains | NUEVOLUTION A/S (DK) | 2020-08-25 | — | — | US | disclosed |
| EP-3405183-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | Arisan Therapeutics Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | NUEVOLUTION A/S (DK) | 2017-12-07 | — | — | US | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
| US-8039479-B2 | Such as 6-{5-Chloro-4-[2-(propane-2-sulfonyl)-phenylamino]-pyrimidin-2-ylamino}-5-isopropoxy-2-piperidin-4-yl-2,3-dihydro-isoindol-1-one; tumors, cancer; inhibition of anaplastic lymphoma, focal adhesion, zeta chain associated protein 70 and/or insulin like growth factor | IRM LLC (BM) | 2011-10-18 | — | — | US | disclosed |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2011-08-04 | — | — | US | disclosed |
| WO-2011085261-A1 | HEDGEHOG INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | State of Oregon Acting By and Through The Oregon State Board of Higher Education On Behalf of The U (US) | 2010-01-21 | — | — | US | disclosed |
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-07-24 | — | — | US | disclosed |
| EP-1858898-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006092510-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-08 | — | — | WO | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176881-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALDH1A1 2982/4885KDM4E 1924/4885SMN1; SMN2 3061/4885 |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | ALDH1A1 1065/4885KDM4E 2421/4885SMN1; SMN2 4438/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | ALDH1A1 617/4885KDM4E 3357/4885SMN1; SMN2 4217/4885 |
| US-20240383884-A1 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | IL2, NFATC1, IL2RA | ALDH1A1 3523/4885KDM4E 2011/4885SMN1; SMN2 4518/4885 |
| US-20170349607-A1 | COMPOUNDS ACTIVE TOWARDS BROMODOMAINS | BRD4, BRD3, BRDT | ALDH1A1 3848/4885KDM4E 626/4885SMN1; SMN2 2459/4885 |
| US-20110190259-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ZAP70, IGF1R, PTK2 | ALDH1A1 2982/4885KDM4E 1924/4885SMN1; SMN2 3061/4885 |
| US-20100016252-A1 | Mannich Base N-Oxide Drugs | ASAH2, MAN2B1, NNT | ALDH1A1 1148/4885KDM4E 3453/4885SMN1; SMN2 757/4885 |
| US-10752640-B2 | Compounds active towards bromodomains | BRD4, BRD3, BRDT | ALDH1A1 3848/4885KDM4E 626/4885SMN1; SMN2 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.